FDA’s Repeated Rejection of Reproxalap: What’s Next for Dry Eye Disease Treatment?
The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press release from Aldeyra Therapeutics. This decision, communicated via a complete response letter, cites a “lack of substantial evidence” for the drug’s efficacy, despite finding no safety or manufacturing concerns.
The Efficacy Question: A Recurring Theme
The FDA’s primary concern revolves around the inconsistency of study results, raising doubts about the reliability and meaningfulness of positive findings. Aldeyra submitted its third new drug application in July 2025, following a previous complete response letter in April 2025, which also pointed to a lack of efficacy in adequately controlled studies. This repeated rejection underscores the high bar for demonstrating clinical benefit in dry eye disease, a condition with a wide range of severities and underlying causes.
What is Reproxalap and Why the Interest?
Reproxalap is designed to reduce inflammation associated with dry eye disease. According to Aldeyra, it’s the only drug with clinical activity within minutes of administration in patients with dry eye disease. This rapid onset of action is a key differentiator, as many current treatments require weeks or months to reveal even modest improvement. The potential for faster relief has fueled significant interest in the drug.
Aldeyra’s Response and Future Plans
Todd C. Brady, MD, PhD, president and CEO of Aldeyra, stated the company “will work with urgency” to address the FDA’s concerns and support the agency in enabling market access. The company’s next steps remain unclear, but could involve additional clinical trials with refined study designs or further analysis of existing data.
Broader Implications for Dry Eye Disease Research
This situation highlights the challenges in developing new treatments for dry eye disease. The condition is complex, and clinical trials can be difficult to design and interpret. The FDA’s scrutiny reflects a desire for robust evidence of efficacy before approving new therapies. This could lead to more rigorous trial designs and a greater focus on identifying biomarkers that can predict treatment response.
Current Treatment Landscape for Dry Eye Disease
Currently, treatments for dry eye disease range from artificial tears and lifestyle modifications to prescription medications like cyclosporine and lifitegrast. These medications aim to reduce inflammation and increase tear production, but often accept weeks or months to provide noticeable relief. The search for faster-acting and more effective therapies continues.
Frequently Asked Questions
- What is reproxalap? Reproxalap is an investigational drug designed to reduce inflammation associated with dry eye disease.
- Why has the FDA rejected reproxalap multiple times? The FDA has cited a lack of substantial evidence demonstrating the drug’s efficacy in clinical trials.
- What are the current treatments for dry eye disease? Current treatments include artificial tears, lifestyle changes, and prescription medications like cyclosporine and lifitegrast.
- What is Aldeyra Therapeutics planning to do? Aldeyra plans to work with the FDA to address their concerns and explore options for future development.
Request a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
Stay informed: For the latest updates on dry eye disease treatments and research, continue to follow Healio Optometry News.
